All Articles

The Danish biotech just locked in billions in financing for its Merus N.V. buyout. It's a high-stakes bet on a new cancer drug to redefine its future.

Bitwarden's new Access Intelligence aims to turn every employee into a security asset, tackling the biggest cause of corporate data breaches head-on.

A new, free tool from Distru and Metrc aims to solve the cannabis industry's labeling nightmare. Is this a game-changer for operators of all sizes?

Great American Media's theatrical leap for its new Christmas film isn't just a movie release—it's a strategic play to redefine holiday entertainment.

After a years-long battle over the $3.1B Verizon sale of Straight Path, IDT is cleared. We break down the court's surprising ruling and what it means.

A new PE firm is betting its strategy on data-driven leadership assessment. Can an algorithm for talent unlock the next wave of investment returns?

A top culinary award is more than a trophy. It's a testament to a flawless global supply chain and an operational blueprint for sustained perfection.

Beyond observability, Dynatrace's new AI agents and AWS specialization signal a strategic push into autonomous cloud operations. What does this mean for investors?

The biotech firm's latest private placement provides crucial cash but also brings heavy dilution and signals financial distress in a tough market.

A new fintech firm is using AI and non-custodial loans to bring instant liquidity to the art world's overlooked mid-market. Will it transform art into a dynamic asset?

From orphan drugs to the massive obesity market, we unpack Hoth Therapeutics' ambitious four-front strategy and the financial currents driving this biotech.

Lithos Carbon’s record delivery proves rock dust can remove CO2, boost farm profits, and set a new standard for the volatile carbon credit market.

An Aussie AI firm bets on a star hire and a risky SPAC merger to power sovereign AI. What does this mean for the infrastructure enabling healthcare's future?

Amid industry chaos, one egg producer's commitment to transparency and humane practices earned it a top award and offers a blueprint for purpose-driven profit.

By repaying debt early, Interpace signals a successful turnaround. See how financial discipline is fueling its focused push into thyroid diagnostics.

With a 60% dose reduction, Bayer's gadoquatrane could set a new safety standard and give the firm a strategic edge in a market under scrutiny.

An activist investor accuses Dye & Durham's board of entrenchment, launching a proxy fight to install a turnaround team and force a strategic reckoning.

Amex's $20k grants for Toronto & Montreal eateries are more than charity; they're a strategic investment in urban vibrancy and small business resilience.

As Bitcoin soars, JDH AI launches a new platform promising zero fees and principal protection. But can it deliver on its bold claims of risk-free returns?

Beyond the AI hype, a new digital workforce is emerging. Artisan Studios' AWS competency validates how autonomous agents are now running business operations.